CTI BioPharma Corp.
CTIC · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $553 | $772 | $708 | $648 |
| - Cash | $24 | $30 | $32 | $66 |
| + Debt | $49 | $50 | $49 | $49 |
| Enterprise Value | $577 | $791 | $725 | $631 |
| Revenue | $24 | $21 | $18 | $12 |
| % Growth | 14.4% | 15.6% | 48% | – |
| Gross Profit | $23 | $20 | $17 | $11 |
| % Margin | 94.9% | 94.5% | 93.7% | 92.6% |
| EBITDA | -$8 | -$14 | -$11 | -$18 |
| % Margin | -32.5% | -65% | -61.7% | -146.8% |
| Net Income | -$22 | -$17 | -$16 | -$23 |
| % Margin | -90.4% | -80.3% | -85.7% | -183.8% |
| EPS Diluted | -0.17 | -0.13 | -0.13 | -0.21 |
| % Growth | -30.8% | 0% | 38.1% | – |
| Operating Cash Flow | -$31 | -$16 | -$15 | -$20 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$31 | -$16 | -$15 | -$20 |